![]() |
Volumn 164, Issue 1, 2004, Pages 107-108
|
Risks and Benefits of Statins in Lupus Erythematosus [3]
a
a
NONE
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ATORVASTATIN;
AUTOANTIBODY;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
SIMVASTATIN;
STATINE DERIVATIVE;
ANTIBODY PRODUCTION;
APOPTOSIS;
AUTOIMMUNE DISEASE;
CARDIOVASCULAR DISEASE;
DERMATOMYOSITIS;
HUMAN;
HYPERCHOLESTEROLEMIA;
IATROGENIC DISEASE;
IMMUNOLOGY;
LETTER;
LICHEN PLANUS;
MORBIDITY;
MORTALITY;
PATHOGENESIS;
PRIORITY JOURNAL;
RASH;
RISK BENEFIT ANALYSIS;
RISK FACTOR;
SYSTEMIC LUPUS ERYTHEMATOSUS;
T LYMPHOCYTE;
|
EID: 0346057969
PISSN: 00039926
EISSN: None
Source Type: Journal
DOI: 10.1001/archinte.164.1.107-b Document Type: Letter |
Times cited : (10)
|
References (11)
|